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Background: Hilar cholangiocarcinoma presents both diagnostic and therapeutic challenges. While
establishing a diagnosis is important for patients considering aggressive treatment, a transperitoneal fine
needle aspiration (FNA) may lead to seeding of the tumour. The aim of the present study was to determine
whether patients who have undergone transperitoneal FNA of the primary tumour have a higher incidence
of metastases.
Patients and Methods: Outcomes of 191 patients enrolled in a neoadjuvant chemoradiotherapy
followed by liver transplantation (LT) from 1 October 1992 to 1 January 2010 were analysed. The incidence
of metastases was compared between those who did or did not undergo a transperitoneal FNA biopsy of
the primary tumour.
Results: A total of 16 patients underwent FNA biopsy. There were six patients with biopsies positive
for adenocarcinoma and 5/6 (83%) had peritoneal metastases at operative staging. Nine patients had
biopsies, which did not demonstrate a tumour, and had no evidence of metastasis. One patient had an
equivocal biopsy. Of those who did not undergo a transperitoneal biopsy, the incidence of peritoneal
metastasis was 8% (14/175), P = 0.0097 vs. positive staging (83%) in those with a diagnostic trans-
peritoneal FNA. Survival at 5 years for those who underwent LT was 74%.
Conclusion: Transperitoneal biopsy of hilar cholangiocarcinoma is associated with a higher rate of
peritoneal metastases, and it should not be performed if a curative approach such as LT is available.
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Introduction
Hilar cholangiocarcinoma (CCA) is a malignant neoplasm
arising from biliary epithelium which has a poor prognosis. The
incidence in the US population is approximately 1.2 in 100 000
although it is much higher in Eastern Europe and Asia, and
overall, appears to be increasing.1–3 Standard therapy for hilar
CCA is resection; however, the majority of patients present with
unresectable tumours due either to involvement of bilateral hilar
structures or the presence of underlying primary sclerosing cho-
langitis, a primary risk factor for the development of hilar
CCA. A protocol for patients with unresectable hilar CCA
involving neoadjuvant chemoradiotherapy followed by liver
transplantation has been developed and has been demonstrated
to be effective, with reported 5-year survival rates of approxi-
mately 75%.4,5
In spite of advances in therapeutic options, establishing the
diagnosis of CCA remains a considerable challenge. The use of
imaging modalities such ultrasound, high-resolution computed
tomography (CT) and magnetic resonance imaging (MRI)
remains the mainstay of CCA diagnosis. While MRI with feru-
moxides (Feridex) and magnetic resonance cholangiopancreatog-
raphy (MRCP) have improved the diagnostic sensitivity and
specificity of cross-sectional imaging for both diagnostic and
staging purposes,6–8 as a result of the biological characteristics of
the tumour, early definitive radiographic diagnosis remains prob-
lematic. Cholangiocarcinoma is a desmoplastic lesion with a
tropism for bile which leads to extension along the bile duct rather
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than growth in a radial diameter. While they have a high specific-
ity, endoscopic brushings and biopsies may remain negative even
with well-established disease.9
Because patients may be candidates for very aggressive
therapy including major surgical resection or chemoradio-
therapy followed by liver transplantation, the importance of a
definitive diagnosis has led some to consider the use of
transperitoneal fine-needle aspiration (FNA) either using a per-
cutaneous or transluminal endoscopic ultrasound (EUS)-guided
approach.10–13 While these techniques may improve the diagnos-
tic yield when compared with biopsies and brushing obtained
with endoscopic retrograde cholangiopancreatography (ERCP),
there are few studies which have directly compared these tech-
niques, as typically, EUS is performed only after ERCP fails to
make the diagnosis. In addition, the risk of tumour seeding from
exposure of the peritoneum to the needle containing the biopsy
specimen is unknown. Tumour seeding from or extension
along percutaneous transhepatic cholangiogram (PTC) tracts
has been described in several prior reports,14–16 although the
incidence of peritoneal metastasis after transperitoneal biopsies
has not been reported. The purpose of the present study
was to determine whether patients who have undergone FNA
biopsy of hilar CCA either via a percutaneous or transluminal
EUS-guided approach are at higher risk of subsequent peritoneal
metastasis.
Methods
Clinical data for all patients with hilar CCA enrolled in the liver
transplant protocol at the Mayo Clinic Rochester between 1
October 1992 and 1 January 2010 were reviewed. The protocol
for combined neoadjuvant chemoradiotherapy followed by liver
transplantation (LT) has been previously described.17,18 Inclusion
criteria included the presence of localised, unresectable hilar
CCA. All patients are evaluated for potential resectability by an
experienced hepatobiliary surgeon and only those with advanced
underlying PSC or bilobar involvement that would preclude
resection are considered for the neoadjuvant protocol. The diag-
nosis is established by endoluminal brushing or biopsy obtained
at the time of ERCP or PTC. Patients with a malignant appear-
ing dominant stricture and with an associated mass lesion
and/or a Ca 19–9 > 100 and/or FISH polysomy are also candi-
dates for enrolment. We do not perform FNA biopsies at our
centre because of the risk, thus all patients with a FNA biopsy
had this performed at an outside facility. Exclusion criteria
are attempted resection with violation of the tumour plane,
prior malignancy within 5 years, or prior abdominal radia-
tion. After neoadjuvant therapy and before LT all patients
underwent a staging laparotomy which involved abdominal
exploration with routine biopsy of perihilar lymph nodes as
well as any lymph nodes or nodules suspicious for tumour.
Only patients with negative staging operations remained eligible
for transplantation.
During the study period, 191 patients enrolled in the LT pro-
tocol were analysed. The incidence of metastatic disease found at
operative staging was compared between those who underwent a
transperitoneal FNA biopsy of the primary tumour vs. those who
did not undergo an FNA biopsy. The site of disease metastasis
within the groups was also compared. In addition, the incidence of
disease recurrence after LT was assessed. Results were compared
using Fisher’s exact test. Five-year survival for patients enrolled in
the combined neoadjuvant chemoradiotherapy followed by LT
was determined by Kaplan–Meier analysis.
Results
Of the 191 patients enrolled in the neoadjuvant chemoradio-
therapy followed by LT protocol, a total of 16 underwent
transperitoneal FNA biopsy of the primary tumour (13 percuta-
neous and 3 EUS). Six patients had a biopsy of the primary
tumour which was positive for adenocarcinoma and nine patients
with hilar CCA underwent transperitoneal biopsies which did not
demonstrate a tumour. One additional patient had equivocal find-
ings on his trans-peritoneal biopsy (‘glandular cells’). He also
developed peritoneal metastasis demonstrated on staging, but he
is not included in the analysis in the FNA (+) group as a result of
his equivocal biopsy result. The demographics of the groups were
similar (see Table 1). In particular, the time from enrolment to
staging was similar in those who underwent a positive or non-
diagnostic FNA biopsy as well as those without an FNA biopsy.
Additionally, there were no identifiable differences between the
tumour characteristics such as the presenting Ca 19-9 level, the
frequency of a mass or size of a mass lesion when present or the
histology. Information such as tumour differentiation or perineu-
ral invasion was not known at enrolment given the limited
amount of diagnostic tissue.
Of the six patients whose biopsies demonstrated malignancy,
5/6 (83%) were found to have disease spread directly into the
peritoneum at operative staging, whereas the remaining patient
had a negative staging operation but died in the peri-operative
period of technical complications related to transplantation (see
Table 2). All nine patients with transperitoneal biopsies which did
not demonstrate a tumour underwent negative operative staging
and underwent subsequent LT, with one death from recurrent
CCA and one death from post-transplant lymphoproliferative dis-
order (PTLD) in this group.
Of the remaining 175 patients who did not undergo transperi-
toneal biopsy, the incidence of peritoneal metastasis at operative
staging was 8% (14/175), P = 0.0097 vs. those found at operative
staging with metastatic disease in those with a positive percuta-
neous FNA by Ficher’s exact test. Overall there were 36 patients
with staging demonstrating metastatic disease of which 14 had
had peritoneal metastasis, 14 had lymph node metastasis, 4 had
direct extension and 4 had intra-hepatic metastasis.
Outcomes for patients who underwent LT after neoadjuvant
treatment for hilar CCA during this time period demonstrated a
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5-year survival of 73% using Kaplan–Meier analysis (see Fig. 1).
There were 125 patients who underwent LT during this period,
with 17 patients who died of recurrent disease and an additional
12 who died of other causes.
Discussion
Establishing the diagnosis of hilar CCA is particularly challenging
because of the biological characteristics of the disease including
tumour location, pauci-cellular nature and longitudinal rather
than radial growth pattern. Percutaneous biopsy and, more
recently, transluminal endoscopic biopsy via EUS guidance both
have been proposed as procedures which may improve the diag-
nostic sensitivity. The current analysis demonstrates a markedly
higher incidence of peritoneal metastasis in patients who undergo
percutaneous or trans-luminal endoscopic FNA biopsy of hilar
CCA, when compared with those who did not undergo a
transperitoneal approach. Given the interval from enrolment to
staging and identifiable tumour characteristics were similar in all
groups, this difference does not appear to be related to more
aggressive or advanced tumours in those with a diagnostic FNA
biopsy.
The benefits of a definitive tissue diagnosis go beyond a prog-
nostic role when potentially curative but highly invasive therapy is
available. While hilar cholangiocarcinoma is associated with poor
survival overall, 5-year survival for patients who are candidates for
surgical resection ranges from 20–40%, depending on the stage of
the tumour.19–24 More recently, neoadjuvant chemoradiotherapy
followed by liver transplantation has proved beneficial for those
with unresectable hilar lesions (those who are not candidates for
surgical resection either because of bilobar involvement or under-
lying liver disease) with a 5-year survival approaching 75%. Resec-
tion and in particular neoadjuvant chemoradiotherapy followed
by LT are associated with significant morbidity. An additional
consideration for patients being considered for LT is the extreme
shortage of available organs. The implications for undergoing
non-beneficial highly invasive therapy, or missing a potentially
curable yet highly lethal malignancy, are considerable. Thus, the
motivation to expand our current diagnostic capabilities is clear.
Table 1 Demographics for patients enrolled in a protocol for chemoradiotherapy followed by liver transplantation (LT) for hilar cholangio-
carcinoma (CCA) from 1993 to January 2010
No biopsy Positive
transperitoneal
biopsy
Negative
transperitoneal
biopsy
Number of patients 175 6 9
Mean age 50 (SD  10.8, range 26–69) 57 (9.9, range 39–69 ) 55 (6.27, range 44–67)
Gender male/female 121 : 54 5 : 1 8 : 1
PSC 70 1 4
Mass lesion present 63 (36%) 1 (16%) 6 (66%)
Mean size of mass, if present 2.9 cm (1.0–4.9 cm) 3.9 cm 2.1 (1.4–3.1)
Ca 19-9 at presentation Mean 878 (0–28,750) 293 (118–522) 519.9 (4–2840)
Positive/suspicious histology by
endoscopic brushing/biopsy
128 (73%) Brushing not performed
(FNA biopsy+)
4 (44%)
Interval from enrolment to
staging (days)
Median 92 (-39a–408)
Mean 121.3
Median 76 (54–249)
Mean 121
Median 89 (77–366)
Mean 150
P = NS for demographics, tumour characteristics and interval from enrolment to staging.
aNegative value as a result of staging performed before enrolment in two cases.
Table 2 Incidence of peritoneal metastasis in patients who under-
went a diagnostic transperitoneal fine needle aspiration (FNA)
biopsy of hilar cholangiocarcinoma (CCA)
No biopsy Positive
transperitoneal
biopsy
Negative
transperitoneal
biopsy
Peritoneal
metastasis
at staging
14/175 (8%) 5/6 (83%)a 0/9
aP = 0.0001 using Fisher's exact test.
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Figure 1 Outcomes for patients who undergo neoadjuvant chemo-
radiotherapy followed by liver transplantation (LT ) for hilar cholang-
iocarcinoma (CCA)
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The use of percutaneous or more recently trans-luminal biop-
sies using EUS guidance have been described as a way to improve
the diagnostic yield. A recent report by Fritscher-Ravens et al. on
EUS-guided FNA of hilar lesions found a definitive diagnosis in
43/44 of patients with hilar strictures which were suspicious, but
not diagnostic of hilar CCA.10 In this series, 31/44 patients were
found to have malignancy whereas 12 were found to have benign
disease (4 of which were later found on clinical or autopsy
follow-up to have been malignant.) The authors reported the
results changed the pre-planned management in about half of the
cases. A second prospective study of 24 patients with suspected
hilar CCA who underwent EUS-guided FNA found a sensitivity of
77%, specificity of 100% and a negative predictive value of 29%.11
In addition to the potential to falsely conclude a benign diagnosis
when a malignancy exists, the primary concern with this approach
is the potential for disease metastasis to the peritoneum as a result
of seeding of tumour cells along the needle tract.
Peritoneal seeding after trans-peritoneal biopsy of hilar CCA
either by percutaneous methods or trans-luminal endoscopic
methods has thus far not been reported. However, peritoneal
spread of hilar CCA after percutaneous biliary drainage has been
reported in multiple case series. A recent case series of 67 patients
with hilar CCA found the incidence of PTC site seeding to be
6%.15 Additionally, peritoneal seeding of hepatocellular carcinoma
after percutaneous FNA or core needle biopsy has also been
reported.25–28 A recent meta-analysis by Silva et al. which is worth
highlighting analysed eight published series and determined the
risk of needle-tract seeding of HCC to be 2.7%.27 Although the
incidence of needle-tract seeding appears to be low, the general
recommendation is to avoid pre-operative percutaneous drainage
of the biliary tree unless it is necessary to relieve obstructive jaun-
dice, and to avoid biopsy of potential HCC due to the risk of
complications such a tumour seeding or bleeding and because the
diagnosis can typically be established by radiographic criteria.
The present study demonstrates a high rate of peritoneal
metastasis (83%) in patients who underwent percutaneous or
trans-luminal FNA biopsy of the primary hilar tumour mass.
Although the overall numbers of patients undergoing trans-
peritoneal FNA biopsy is small (n = 6), all were candidates for a
potentially curative therapy. The rate of disease metastasis in those
who did not undergo a percutaneous FNA biopsy was low (20%
overall, with an 11% incidence of peritoneal metastasis.) A
primary weakness of the present study is that patients were non-
randomised, although there were no remarkable demographic
differences between the groups. The present study is also limited
by the retrospective nature; however, it is unlikely that a prospec-
tive randomised controlled trial comparing transperitoneal FNA
biopsy with other diagnostic methods could be performed. This is
because of the relative infrequency of this diagnosis, as well as the
high mortality for patients not eligible for potentially curable
therapy which would make it difficult to demonstrate peritoneal
seeding as patients may succumb before this becoming clinically
evident.
The incidence of peritoneal seeding of hilar CCA in the current
analysis appears higher than that reported after PTC for hilar CCA
and also higher than that after FNA for HCC. The reasons for this
are unknown. The amount of peritoneal exposure for FNA biopsy
for CCA may be greater than of the peritoneal exposure for PTC
or HCC as in both of the later cases the liver is adjacent to the
abdominal wall which limits peritoneal exposure. It may also be
that after chemoradiotherapy, patients are more susceptible to
peritoneal spread because of relative immunosuppression or other
changes to the peritoneal surfaces, although this seems unlikely as
the transperitoneal biopsy preceded the neoadjuvant therapy by
weeks to months in all cases.
Neoadjuvant chemoradiotherapy followed by liver trans-
plantation offers excellent survival benefit for patients with early
stage yet unresectable disease. Patients with resectable disease have
5-year survival rates which are approximately 20–40% depending
on the stage of disease. Based on the current analysis, the risk of
peritoneal seeding is prohibitively high and therefore percutane-
ous or trans-luminal endoscopic FNA of hilar CCA should be
avoided in patients who may be candidates for potentially curative
therapies.
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